新发心血管疾病的类风湿关节炎患者骨质疏松性椎体骨折风险增加:台湾地区回顾性全国队列研究
该回顾性全国队列研究纳入2000至2010年新诊断类风湿关节炎患者中1267例新发心血管疾病者与1267例无心血管疾病者,发现新发心血管疾病组骨质疏松性椎体骨折风险显著增高(aHR 1.47,95%CI 1.19-1.81,p<0.001),年龄>40岁和女性为显著危险因素,他汀治疗与风险降低相关,而低剂量糖皮质激素或羟氯喹的保护作用需进一步验证。
要点
- 类风湿关节炎合并新发心血管疾病患者骨质疏松性椎体骨折风险较无心血管疾病者增高(aHR 1.47,95%CI 1.19-1.81,p<0.001)。
- 年龄>40岁和女性是类风湿关节炎合并心血管疾病患者发生骨质疏松性椎体骨折的显著危险因素。
- 他汀治疗与骨质疏松性椎体骨折风险降低相关(aHR 0.50),低剂量糖皮质激素或羟氯喹的保护作用需进一步验证。
核心结论
- 类风湿关节炎合并新发心血管疾病患者骨质疏松性椎体骨折风险显著增加,尤其是40岁以上女性,他汀治疗可能降低该风险。
- 低剂量糖皮质激素或羟氯喹对骨质疏松性椎体骨折风险的保护作用需进一步验证。
研究设计与样本
- 回顾性全国队列研究,使用2000至2010年台湾地区全国数据库,从30507例新诊断类风湿关节炎患者中纳入1267例类风湿关节炎合并新发心血管疾病患者和1267例无心血管疾病患者。
- 主要结局为骨质疏松性椎体骨折的发生,采用Cox比例风险模型并经年龄、性别和合并症调整。
主要发现
- 类风湿关节炎合并心血管疾病组发生骨质疏松性椎体骨折的调整风险比无心血管疾病组高1.47倍(95%CI 1.19-1.81,p<0.001)。
- 在类风湿关节炎合并心血管疾病患者中,年龄>40岁和女性是发生骨质疏松性椎体骨折的显著危险因素。
- 以未用药患者为参照,接受他汀治疗者骨质疏松性椎体骨折的aHR为0.50,接受低剂量糖皮质激素者为0.57,接受羟氯喹者为0.12,均显著降低。
局限性
- 低剂量糖皮质激素或羟氯喹对骨质疏松性椎体骨折风险的保护作用需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Both cardiovascular diseases (CVD) and osteoporosis are common comorbidities in rheumatoid arthritis (RA) patients. Although accumulating evidence indicates a link between CVD and osteoporotic fracture, whether CVD contributes to osteoporotic fracture risk in RA has yet to be explored. We examined the incidence rate and risk factors of osteoporotic vertebral fracture in RA patients with new-onset CVD (RA-CVD) and evaluated the effects of medications on such fracture risk. METHODS: A retrospective study was conducted using a nationwide database from 2000 to 2010: 1267 RA-CVD and 1267 non-CVD patients were enrolled from 30,507 patients with newly diagnosed RA. The main outcome was the development of osteoporotic vertebral fracture. After being adjusted for age, gender, and comorbidities, the Cox proportional hazard model was used to identify independent factors contributing to osteoporotic vertebral fracture. RESULTS: The adjusted hazard ratio (aHR) of developing osteoporotic vertebral fracture was 1.47-fold greater in RA-CVD group than in non-CVD group (95% confidence interval 1.19-1.81, p < 0.001). Both the age above 40 years and female gender were significant risk factors for developing osteoporotic vertebral fracture in RA-CVD patients. Using patients not taking medication as a reference group, the aHR of osteoporotic vertebral fracture was significantly lower in those receiving statins (0.50), low-dose corticosteroids (0.57), or hydroxychloroquine (0.12). CONCLUSIONS: The risk of osteoporotic vertebral fracture was significantly increased in RA-CVD patients, particularly women above 40 years of age, and could be reduced by statin therapy. However, the protective effect of low-dose corticosteroids or hydroxychloroquine on osteoporotic vertebral fracture risk needs further validation.
引用
- Hong WJ, Chen W, Yeo KJ, et al. Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan. Osteoporos Int. 2019. PMID: 31127317. doi:10.1007/s00198-019-04966-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。